Screener
Organon OGN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Repayments of debt | (32) | (93) |
| Employee withholding taxes related to stock-based awards | (1) | (1) |
| Dividend payments | (5) | (71) |
| Net Cash Flows Used in Financing Activities | (38) | (75) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (31) | 44 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 542 | (128) |
| Cash and Cash Equivalents, Beginning of Period | 574 | 675 |
| Cash and Cash Equivalents, End of Period | $1,116 | $547 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's cash & equivalents?
- Organon (OGN) reported cash & equivalents of $1.12B in Q1 2026.
- How has Organon's cash & equivalents changed year-over-year?
- Organon's cash & equivalents increased by 104.0% year-over-year, from $547M to $1.12B.
- What is the long-term trend for Organon's cash & equivalents?
- Over 5 years (2020 to 2025), Organon's cash & equivalents has grown at a 116.7% compound annual growth rate (CAGR), from $12M to $574M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Organon's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude